Innate Pharma rises ahead of cancer antibody data presentation

Innate Pharma SA

17/09/2021 11:48

** U.S.-listed shares of France-based drugmaker Innate
Pharma  IPH.PA ,  IPHA.O  rise 14.8% to $6.60 premarket - on
track for a third straight day of gains
    ** AstraZeneca Plc  AZN.L  to present data from a mid-stage
study testing its drug, durvalumab, in combination with IPHA's
antibody candidate, monalizumab, in non-small cell lung cancer
on Sept. 17  urn:newsml:reuters.com:*:nGNX9mfMK7
    ** SVB Leerink is optimistic about the data and raises PT on
IPHA to $9 from $7, implying an upside of 56.5% to stock's last
close
    ** The trial is not only a major positive for
IPHA promising to revive interest in its pipeline, but for the
immuno-oncology industry as a whole, says brokerage, which rates
IPHA "outperform"
    ** AZN to present the data at the European Society for
Medical Oncology (ESMO) Virtual Congress
    ** IPHA was up 40.6% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))